Saturday , September 26 2020
Home / korea / BioEleven-Immunobiome Signs MOU to “ Build Models of Human Microbioma Disease & # 39; '

BioEleven-Immunobiome Signs MOU to “ Build Models of Human Microbioma Disease & # 39; '



[ad_1]

Establishment of a human microbiome evaluation model and targeted microbiome targeted therapeutic research

▲ (left) CEO of Immunhyuk, CEO of Immuno Biom (right) Kim, Suk-jin Director of the Bio-Eleven Research Institute (Bio-Eleven)

▲ (left) CEO of Immunhyuk, CEO of Immuno Biom (right) Kim, Suk-jin Director of the Bio-Eleven Research Institute (Bio-Eleven)

BioEleven probiotic specialist research institute announced on the 19th that they signed a business agreement with Immunobiom Co., Ltd., a microbioma disease-specific research company, and will collaborate on the formation of a human microbioma disease model.

Together, the two companies will build a model for evaluating human microbiomas and research into disease-specific microbioma targeted therapies, which will accelerate the development of pharmbiotics, medical probiotics.

Specifically, if human enteric microbiomas are implanted into sterile mice and humanized microbioma models have the same composition as the human enterobacteriaceum ecosystem, microbes are currently being processed at the BioEleven Institute. The company hopes to increase mutual benefits between the two companies, such as the use of ohm research and the development of targeted microbiome treatments specifically for the disease being developed.

Immunobiom was founded in June by POSTECH Professor, Department of Biological Sciences and Biotechnology Convergence, to develop immune redesign and treatment of diseases that cannot be treated. Lim is currently the chair of the International Probiotic Conference (IPC) and leads the field of domestic immunotherapy and probiotics through various research activities including fecal transplants, probiotics, and microbial derivatives.

Kim Seok-jin, director of the Bio-Eleven Research Institute, said, "We are pleased to collaborate with Prof. Yuh Hyeok, the highest authority in the field of probiotics in Korea." Word.

Meanwhile, the BioEleven Research Institute has analyzed thousands of enteric microorganisms over the years by introducing intestinal bacterial analysis (GMA) services for the first time in Korea in 2013. Based on this experience, the company established Korea's first bank, Gold Biom, in 2017 and is conducting various research activities to improve the microbial ecosystem of modern humans.

[ad_2]
Source link